08 Aug management Posted at 09:36h in by adminaltheia 0 Comments 0 Likes GUIDO GUIDI, MDCHAIRMANGUIDO GUIDI, MDCHAIRMAN– 35 years at global top positions in big pharmaceuticals at all levels. Managed staff over 7,000 employees with turnover over 7b€ – Head Pharma Region Europe Novartis – Head Oncology Europe Novartis – Brought various drugs from clinical development to market in oncology and general medicine among them Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge – Originated and chaired the first edition of Bioupper, the Novartis accelerator for early stage projects in Italy – Chairman of the Novartis European Executive Committee – Member of the Innovation Management Board in charge of the R&D program of Pharma division – Member of the Novartis Portfolio Management Board in charge of the research and development programs of the Oncology division – Winner of the Talent Development Award (2008) – Winner of the Business Result Excellence Award from CEO Daniel Vasella (2008) – Member of the EFPIA Executive Committee – Head Oncology South Europe Novartis – Different medical positions in Novartis, Sandoz, Roussel-UCLAF, GSK GABRIELE CAMPI, PhDCO-FOUNDER & MANAGING PARTNERGABRIELE CAMPI, PhDCO-FOUNDER & MANAGING PARTNERGabriele Campi, PhD is an immunologist with an integrate background sharing 10+ years of academic research between San Raffaele Hospital, Milan and New York University, New York City and 6+ years in Venture Capital and Technology Transfer with different positions in VC funds in Italy, Switzerland and in UK. Gabriele also worked for TTFactor, the Technology Transfer Office of the European Institute of Oncology (IEO) and the FIRC Institute of Molecular Oncology (IFOM) as a busness development manager dealing with the transfer of early stage/pre-clinical projects to industry. He published seminal papers within the concept of the immunological synapse and T cell activation and shares a solid expertise within the process of technology transfer and biotechnology related early stage investments. EDOARDO NEGRONI, MBACO-FOUNDER & MANAGING PARTNEREDOARDO NEGRONI, MBACO-FOUNDER & MANAGING PARTNER– 20 years in BioPharma, Medical Devices and Consulting with different management roles in various European countries. Managed staff over 100 employees with turnover over 30M€ – CEO Inorgen (Drug Discovery Engine), UK and Italy – Deployment of the business model, marketing with pharma companies, VCs and relevant stakeholders for partnering activities – Agreement with a Drug Discovery company for asset co-development – Mentoring of two academic early stage projects oncology concerning tumor microenvironment and precision medicine – Member of the start-up commission at Tor Vergata University in Rome – CBO International Operations OPIS (Clinical CRO), Italy – Launched the expansion of international operations – VP Strategy and Organization La-ser Europe, UK. Pharma Consulting in health science – CBO Northern and Southern Europe, France – Country Manager Italy Stallergenes, Italy – Hit regularly sales and EBIT targets – Built and managed successful pharma operations teams in Italy, Spain, The Netherlands and other countries – 1 drug (Oralair) brought to market in Italy and Spain – Rationalisation of the drug of named patient products portfolio (from 150+ to 10 products) to follow a specialty medicine’s pharmaceutical approach – Sales and Marketing Director, Air Liquide Medical Systems, Italy – Various management roles in industry, France and Italy PAOLO RIZZARDI, MDVENTURE PARTNERPAOLO RIZZARDI, MDVENTURE PARTNERPaolo Rizzardi, MD, internist, is Co-Founder and Managing Partner of AurorA-TT, a Technology Transfer initiative fully focused in the biotech sector, and Co-Founder, Chairman&CEO of Altheia Science. He combines a strong scientific background with managerial skills gained in substantially contributing to successfully develop biotechnology companies and to achieve the market approval of advanced therapy medicinal products in the cell&gene therapy and oncology field. After spending more than 10 years in academia in Italy, UK, and Switzerland in developing programs for innovative immune-based/vaccination strategies in patients with HIV/AIDS, he worked for more than 15 years in the cell&gene therapy biotech sector, developing a unique expertise in R&D, CMC, clinical and business development, development, engineering, and IP from target validation to market approval. He published over 90 peer-reviewed manuscripts and textbook chapters (4500+ citations, h-index 32), including seminal contribution to the field of immunopathogenesis and innovative treatment of HIV infection. PIERLUIGI PARACCHI, DEcVENTURE PARTNERPIERLUIGI PARACCHI, DEcVENTURE PARTNERPierluigi Paracchi is Co-Founder and Venture Consultant of AurorA-TT, a Technology Transfer initiative fully focused in the biotech sector, and Co-Founder, Board Member of Altheia Science. He has more than 15 years of experience as Venture Capitalist and Biotech Entrepreneur. He was Founder & CEO of Quantica, the first Italian VC firm exclusively dedicated to research and academic spin-out companies and Venture Consultant at Sofinnova Partners. He was investors and Board Member at EOS – Ethical Oncology Science, acquired by Clovis Oncology for 470M. He is Co-Founder and CEO of Genenta Science, spin-out from San Raffaele Hospital: gene therapy for tumor treatment; Board Member at Assobiotec and Chairman of the SMEs group.